Ilmarinen Mutual Pension Insurance Co Has $2.95 Million Position in IQVIA Holdings Inc. (NYSE:IQV)

Ilmarinen Mutual Pension Insurance Co increased its holdings in shares of IQVIA Holdings Inc. (NYSE:IQV) by 50.0% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 15,000 shares of the medical research company’s stock after buying an additional 5,000 shares during the period. Ilmarinen Mutual Pension Insurance Co’s holdings in IQVIA were worth $2,948,000 at the end of the most recent quarter.

A number of other institutional investors have also recently added to or reduced their stakes in the business. Captrust Financial Advisors increased its holdings in IQVIA by 30.8% in the third quarter. Captrust Financial Advisors now owns 8,188 shares of the medical research company’s stock valued at $1,940,000 after purchasing an additional 1,927 shares during the period. Benjamin Edwards Inc. acquired a new stake in shares of IQVIA in the third quarter valued at about $261,000. Hilltop Holdings Inc. bought a new position in shares of IQVIA during the third quarter worth about $446,000. Point72 DIFC Ltd lifted its stake in shares of IQVIA by 199.5% in the third quarter. Point72 DIFC Ltd now owns 2,289 shares of the medical research company’s stock worth $542,000 after acquiring an additional 4,589 shares during the period. Finally, Quantinno Capital Management LP boosted its holdings in IQVIA by 82.0% in the third quarter. Quantinno Capital Management LP now owns 18,059 shares of the medical research company’s stock valued at $4,280,000 after acquiring an additional 8,138 shares during the last quarter. 89.62% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

IQV has been the topic of a number of analyst reports. StockNews.com lowered shares of IQVIA from a “buy” rating to a “hold” rating in a research note on Wednesday, March 12th. Truist Financial reaffirmed a “buy” rating and set a $263.00 price target (up previously from $261.00) on shares of IQVIA in a research report on Monday, February 10th. JPMorgan Chase & Co. lowered their price objective on IQVIA from $240.00 to $232.00 and set an “overweight” rating for the company in a research report on Tuesday, February 18th. Bank of America decreased their target price on IQVIA from $255.00 to $235.00 and set a “buy” rating for the company in a research note on Friday, December 13th. Finally, Stephens started coverage on IQVIA in a research note on Friday, December 20th. They issued an “overweight” rating and a $250.00 price target on the stock. Five analysts have rated the stock with a hold rating, sixteen have assigned a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $249.05.

IQVIA Price Performance

IQVIA stock opened at $154.63 on Friday. The business’s 50 day simple moving average is $189.67 and its 200 day simple moving average is $203.82. IQVIA Holdings Inc. has a 12 month low of $154.35 and a 12 month high of $252.88. The company has a market cap of $27.26 billion, a price-to-earnings ratio of 20.62, a PEG ratio of 1.99 and a beta of 1.46. The company has a current ratio of 0.84, a quick ratio of 0.84 and a debt-to-equity ratio of 2.12.

IQVIA (NYSE:IQV) last issued its quarterly earnings results on Thursday, February 6th. The medical research company reported $2.90 EPS for the quarter, missing analysts’ consensus estimates of $3.11 by ($0.21). IQVIA had a net margin of 8.91% and a return on equity of 28.81%. Sell-side analysts forecast that IQVIA Holdings Inc. will post 10.84 EPS for the current year.

About IQVIA

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.